Clinical Research Studies

This study is being done to learn more about AMG 570 in people with systemic lupus erythematosus (SLE). The purpose of the study is to evaluate safe and effective doses of AMG 570 for the treatment of active SLE in patients who are not responding to the current standard of care. In autoimmune diseases such as SLE, it is thought that excessive inflammation is caused by the over-activity of two particular immune cells: T cells and B cells. Many treatments for autoimmune diseases work by targeting and blocking either T cells or B cells. But AMG 570 is designed to block both cell types, by targeting and blocking two molecules important for T cell and B cell over-activity, named ICOSL and BAFF. In previous studies, this dual-target approach has been found to be more effective than only targeting one cell type.